emerg
pandem
result
need
urgent
develop
vaccin
drug
conduct
clinic
trial
fight
outbreak
time
constraint
associ
develop
vaccin
effect
drug
drug
repurpos
altern
treatment
method
use
treat
patient
infect
viru
acquir
systemat
review
provid
overview
molecular
mechan
action
repurpos
drug
altern
treatment
medicin
use
attenu
diseas
research
articl
grey
literatur
includ
these
govern
report
offici
news
onlin
identifi
databas
search
engin
full
content
total
articl
fulfil
inclus
criteria
analyz
inform
drug
ritonavir
lopinavir
oseltamivir
remdesivir
favipiravir
chloroquin
tradit
chines
medicin
decemb
novel
type
viral
pneumonia
discov
wuhan
hubei
provinc
china
intern
committe
taxonomi
virus
offici
name
diseas
corona
viru
diseas
viru
new
corona
viru
rapidli
spread
among
human
world
led
hundr
thousand
case
within
month
result
th
march
world
health
organ
declar
pandem
defin
worldwid
spread
new
diseas
th
march
laboratoryconfirm
case
report
global
total
number
death
reach
peopl
worldwid
distribut
case
th
march
cet
shown
figur
cov
singlestrand
rna
virus
look
like
crown
microscop
coronam
latin
word
crown
contain
spike
glycoprotein
envelop
subfamili
orthocoronavirina
coronavirida
famili
order
nidoviral
classifi
four
genera
cov
alphacov
betacov
deltacov
gammacov
categor
betacov
ellipt
round
often
pleomorph
form
diamet
nm
like
betacov
sensit
ultraviolet
ray
heat
effect
kill
lipid
solvent
acut
respiratori
ill
appear
common
manifest
infect
spectrum
symptomat
infect
rang
mild
sever
infect
sever
mild
clinic
symptom
initi
stage
occur
time
inocul
earli
establish
diseas
peopl
involv
incub
period
associ
mild
often
nonspecif
symptom
malais
fever
dri
cough
period
multipli
establish
resid
host
primarili
focus
respiratori
system
bind
target
use
angiotensinconvert
enzym
receptor
human
cell
moder
clinic
symptom
second
stage
establish
pulmonari
diseas
viral
multipl
local
inflamm
lung
norm
stage
patient
develop
viral
pneumonia
cough
fever
possibl
hypoxia
defin
mmhg
imag
chest
roentgenogram
computer
tomographi
reveal
bilater
infiltr
ground
glass
opac
blood
test
reveal
increas
lymphopenia
along
transamin
sever
clinic
symptom
approxim
everi
patient
transit
third
sever
stage
ill
manifest
extrapulmonari
system
hyperinflamm
syndrom
stage
marker
system
inflamm
appear
elev
infect
result
decreas
helper
suppressor
regulatori
cell
count
stage
shock
vasoplegia
respiratori
failur
even
cardiopulmonari
collaps
discern
system
organ
involv
even
myocard
manifest
stage
latest
trend
show
humantohuman
spread
main
mode
transmiss
believ
happen
respiratori
droplet
sneez
cough
aerosol
transmiss
also
possibl
close
area
infect
might
also
happen
someon
touch
contamin
surfac
touch
eye
nose
mouth
although
symptomat
peopl
frequent
sourc
spread
possibl
transmiss
symptom
develop
even
individu
remain
asymptomat
exclud
moreov
period
individu
infecti
uncertain
durat
viral
shed
also
variabl
data
suggest
use
social
distanc
best
way
control
pandem
sever
countri
taken
measur
mobil
restrict
drastic
social
distanc
school
closur
travel
ban
could
significantli
disrupt
econom
social
stabil
moment
therapeut
approach
handl
support
neither
vaccin
prevent
infect
clinic
approv
antivir
drug
treat
therefor
identifi
drug
treatment
option
soon
possibl
critic
respond
pandem
clinic
trial
vaccin
current
underway
potenti
vaccin
administ
volunt
phase
safeti
trial
usa
govern
howev
efficaci
long
immun
last
peopl
might
becom
infect
even
possess
high
level
antibodi
becom
clear
least
one
year
inject
furthermor
safeti
develop
vaccin
unknown
laboratori
test
conduct
parallel
clinic
trial
phase
owe
emerg
pandem
unknown
efficaci
safeti
vaccin
use
might
caus
diseas
enhanc
vaccin
subject
might
develop
even
sever
form
diseas
subject
vaccin
shown
studi
sar
vaccin
vaccin
ferret
develop
damag
inflamm
liver
infect
viru
drug
success
develop
control
howev
numer
effort
underway
worldwid
particularli
china
therefor
drug
repurpos
use
exist
altern
medicin
use
effect
method
treatment
patient
comprehens
review
review
use
exist
drug
altern
treatment
method
discuss
mode
action
molecular
mechan
perspect
attenu
human
system
section
may
divid
subhead
provid
concis
precis
descript
experiment
result
interpret
well
experiment
conclus
drawn
primari
search
identifi
publish
unpublish
paper
pubm
sciencedirect
googl
scholar
semant
scholar
googl
search
engin
duplic
exclud
leav
articl
screen
titl
analysi
elig
publish
unpublish
paper
identifi
exclud
paper
differ
theme
systemat
review
conclus
content
paper
fulli
analyz
exclud
accord
exclus
criteria
medic
administr
treatment
march
divid
drug
class
differ
subclass
individu
drug
identifi
differ
within
drug
class
repurpos
drug
use
treatment
consist
drug
ritonavir
lopinavir
oseltamivir
remdesivir
favipiravir
chloroquin
tcm
shuang
huang
lian
kou
fu
ye
tcm
combin
bu
huan
jin
zheng
qi
san
da
yuan
yin
xue
bi
jing
inject
qing
fei
pai
du
tang
articl
review
consist
guidelin
clinic
trial
registri
offici
news
vitro
vivo
studi
report
present
vitro
vivo
outcom
clinic
find
treatment
efficaci
flowchart
illustr
progress
studi
select
number
stage
shown
figur
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
systemat
review
provid
overview
previou
studi
exist
drug
tcm
repurpos
treatment
discuss
initi
mechan
action
drug
molecular
perspect
treatment
coronavirus
virus
mechan
action
drug
give
risen
medic
use
treat
sinc
outbreak
diseas
decemb
develop
vaccin
efficaci
clinic
trial
time
consum
recent
report
launch
multiarm
multicountri
clinic
trial
drug
remdesivir
lopinavir
ritonavir
kaletra
kaletra
interferon
beta
chloroquin
march
even
though
systemat
review
method
search
literatur
cover
medic
repurpos
drug
use
march
find
relev
still
date
drug
test
clinic
trial
launch
known
solidar
cover
review
abbvi
inc
patent
two
antiretrovir
proteas
inhibitor
ritonavir
lopinavir
ritonavir
also
known
norvir
deriv
lvalin
wherea
lopinavir
structur
relat
ritonavir
illustr
figur
initi
develop
standalon
antivir
agent
treatment
hiv
infect
howev
combin
obtain
effici
drug
respons
sold
brand
name
kaletra
combin
ritonavir
lopinavir
ie
kaletra
hypothes
function
bind
activ
site
sarscov
pro
enzym
prior
discoveri
synthesi
lopinavir
ritonavir
use
treatment
infect
revers
inhibit
hiv
proteas
block
access
proteas
activ
site
thu
prevent
process
hiv
gag
gagpol
polyprotein
result
format
immatur
hiv
particl
infecti
howev
extrem
high
mutat
rate
vivo
given
rise
strain
resist
ritonavir
rise
ritonavirresist
hiv
strain
led
develop
effect
drug
combat
hiv
infect
one
lopinavir
lopinavir
proteas
inhibitor
function
similarli
ritonavir
revers
bind
hiv
proteas
activ
site
prevent
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
gag
gagpol
polyprotein
process
compar
ritonavir
lower
amount
lopinavir
requir
achiev
nm
versu
nm
although
effect
term
concentr
requir
achiev
vitro
experi
human
liver
microsom
reveal
lopinavir
undergo
oxid
metabol
cytochrom
enzym
thu
reduc
bioavail
lopinavir
combat
lopinavir
administ
togeth
ritonavir
inhibit
enzym
activ
high
rate
mutat
hiv
given
rise
drugresist
lopinavirritonavir
hiv
strain
lopinavirritonavir
act
select
pressur
combin
drug
togeth
provid
better
efficaci
hiv
proteas
inhibitor
drug
first
repurpos
drug
use
treat
patient
diagnos
covid
administr
ritonavir
lopinavir
treatment
might
owe
similar
genom
sequenc
sarscov
approxim
origin
genu
sarscov
merscov
betacoronaviru
therefor
therapi
drug
develop
treatment
sarscov
merscov
could
use
develop
therapeut
assum
mechan
similar
famili
member
lopinavirritonavir
administ
patient
diagnos
moder
stage
second
stage
establish
pulmonari
diseas
viral
multipl
molecular
dynam
simul
suggest
lopinavir
ritonavir
abl
inhibit
sarscov
pro
enzym
requir
process
sarscov
polyprotein
contain
replicas
enzym
bind
enzym
activ
site
neither
higher
bind
affin
howev
bind
analysi
show
half
lopinavir
left
outsid
catalyt
site
one
ritonavir
benzen
side
chain
might
long
perfectli
fit
substrat
bind
pocket
would
lead
ritonavir
lopinavir
poor
efficaci
reflect
weak
vitro
activ
sarscov
anoth
studi
suggest
lopinavir
ritonavir
effect
sarscov
replic
nelfinavir
inhibitor
effect
sarscov
replic
despit
effect
sarscov
replic
lopinavir
antivir
activ
sarscov
one
studi
suggest
lopinavir
synergist
effect
use
ribavirin
studi
conduct
lopinavir
ritonavir
effect
merscov
show
although
lopinavir
ritonavir
antivir
activ
merscov
effect
lower
interferon
beta
remdesivir
recent
studi
reveal
util
cell
entri
method
use
sarcov
name
reli
receptor
prime
spike
protein
clinic
proven
proteas
inhibitor
receptor
alreadi
avail
form
camostat
mesyl
studi
also
mention
antibodi
produc
sarscov
use
combat
albeit
lower
effici
antibodi
recov
recov
patient
could
use
combat
although
prevent
measur
earli
stage
infect
howev
method
success
use
treat
serious
ill
patient
china
patient
show
improv
within
hour
oseltamivir
anoth
synthet
prodrug
figur
use
treatment
capabl
inhibit
neuraminidas
enzym
surfac
influenza
viru
particl
drug
manufactur
hoffmannla
roch
inc
patent
held
gilead
scienc
inc
sold
brand
name
tamiflu
drug
use
treat
influenza
influenza
b
infect
well
prevent
influenza
infect
oseltamivir
administ
oral
prodrug
form
oseltamivir
phosphat
treatment
prophylaxi
influenza
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
influenza
b
infect
oseltamivir
phosphat
readili
absorb
gastrointestin
tract
convert
hepat
esteras
activ
form
oseltamivir
carboxylas
competit
inhibitor
neuraminidas
found
influenza
influenza
b
revers
bind
activ
site
neuraminidas
prevent
neuraminidas
cleav
sialic
acid
residu
found
surfac
host
cell
prevent
entri
viru
uninfect
cell
releas
newli
form
virion
infect
cell
reduc
viral
shed
infect
viru
oseltamivir
elimin
bodi
urin
vitro
studi
shown
oseltamivir
phosphat
oseltamivir
carboxyl
suscept
metabol
cytochrom
enzym
although
use
prevent
influenza
infect
consumpt
oseltamivir
substitut
influenza
vaccin
common
side
effect
oseltamivir
nausea
vomit
rang
mild
moder
sever
side
effect
mitig
consum
oseltamivir
food
led
mark
improv
pneumonia
condit
hour
test
neg
hour
drug
cocktail
administ
next
day
subsequ
test
next
day
gave
neg
result
howev
synergist
effect
combin
drug
unclear
oseltamivir
inhibit
sarscov
merscov
like
lopinavir
ritonavir
repurpos
ritonavir
lopinavir
oseltamivir
treatment
current
studi
compani
abbvi
inc
remdesivir
rdv
develop
code
adenosin
nucleotid
analogu
prodrug
develop
gilead
scienc
treatment
ebola
viru
infect
figur
sever
studi
reveal
broadspectrum
antivir
activ
oseltamivir
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
addit
hydroxyl
group
blue
circl
remdesivir
inhibit
replic
mer
rna
strand
cycl
nucleotid
addit
shield
antivir
drug
remov
coronaviru
proofread
enzym
abolish
nucleotid
analog
wherea
nitrogen
yellow
circl
function
proton
donor
acceptor
hydrogen
bond
uracil
base
ident
bind
site
doubl
strand
rna
adenosin
phosphat
group
green
circl
creat
protect
group
mcguigan
protid
transport
antivir
compound
cell
phosphoryl
ident
normal
nucleotid
triphosph
recogn
polymeras
cell
import
uniqu
part
nucleotid
analog
addit
cyano
group
red
circl
elimin
side
effect
blockag
mitochondri
rna
polymeras
exhibit
mice
remdesivir
block
prolifer
rna
virus
host
bodi
prematur
termin
viral
rna
transcript
remdesivir
metabol
activ
nucleosid
triphosph
work
incorpor
competitor
adenosin
triphosph
mechan
interfer
action
viral
rna
polymeras
caus
delay
chain
termin
lead
decreas
viral
rna
product
base
vitro
test
util
primari
human
lung
epitheli
cell
cultur
remdesivir
potent
antivir
batcov
zoonot
batcov
sarscov
merscov
circul
contemporari
humancov
comparison
antivir
drug
lopinavir
ritonavir
interferon
beta
remdesivir
display
superior
antivir
activ
vitro
use
cell
mersnanoluciferas
vivo
transgen
mous
human
merscov
receptor
dipeptidyl
peptidas
sheahan
studi
state
prophylact
therapeut
remdesivir
improv
pulmonari
function
reduc
lung
viral
load
sever
lung
patholog
data
prompt
efficaci
test
prophylact
therapeut
remdesivir
treatment
nonhuman
primat
model
merscov
infect
rhesu
macaqu
induct
clinic
diseas
merscov
complet
prevent
inhibit
merscov
format
lung
lesion
format
prophylact
remdesivir
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
treatment
initi
h
prior
inocul
data
also
strongli
suggest
clinic
benefit
therapeut
treatment
reduc
viru
replic
sever
lung
lesion
improv
sever
lung
patholog
vitro
vivo
studi
sheahan
might
help
improv
ill
patient
sever
categori
manifest
extrapulmonari
system
hyperinflamm
syndrom
make
remdesivir
high
potenti
drug
candid
would
effect
combat
recent
studi
wang
et
al
report
chloroquin
remdesivir
effect
inhibit
infect
vero
cell
drug
even
use
treat
first
us
patient
washington
diagnos
owe
pneumonia
condit
use
remdesivir
dramat
improv
patient
condit
phase
iii
clinic
trial
china
unit
state
hong
kong
republ
korea
singapor
franc
approv
evalu
efficaci
safeti
drug
patient
us
nation
librari
medicin
patient
experiment
group
receiv
initi
dose
mg
remdesivir
follow
daili
dose
mg
remdesivir
intraven
infus
addit
standard
care
therapi
wherea
patient
control
group
receiv
standard
care
therapi
dose
rdv
placebo
accord
clinic
trial
data
us
nation
librari
medicin
clinic
trial
still
underway
broad
conclus
made
efficaci
safeti
drug
favipiravir
anoth
nucleotid
analogu
use
treat
favipiravir
fpv
develop
toyama
chemic
approv
japan
treatment
influenza
viru
infect
figur
favipiravir
demonstr
antivir
activ
wide
rang
rna
virus
includ
noroviru
zika
viru
footandmouth
diseas
viru
fmdv
rabi
ebola
viru
like
remdesivir
favipiravir
inhibit
viral
rna
synthesi
chain
termin
favipiravir
metabol
ribofuranosyl
rtp
incorpor
grow
rna
strand
incorpor
singl
molecul
favipiravirrtp
partial
prevent
extens
rna
strand
doubl
incorpor
favipiravirrtp
molecul
complet
block
extens
mechan
effici
inhibit
viral
rnadepend
rna
polymeras
function
studi
also
report
induc
lethal
mutagenesi
influenza
viru
hepat
c
viru
infect
reduc
viral
titr
vitro
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
ebovspecif
antibodi
suggest
vivo
suppress
viru
replic
favipiravir
allow
host
assembl
virusspecif
adapt
immun
respons
tackl
infect
howev
favipiravir
therapeut
effect
hardli
benefici
termin
stage
diseas
small
anim
data
gener
cautiou
optim
translat
find
nonhuman
primat
trial
prophylact
complement
therapeut
treatment
favipiravir
ebov
nonhuman
primat
success
inhibit
viral
product
extend
surviv
time
concentrationdepend
manner
anoth
pharmacokinet
studi
favipiravir
nonhuman
primat
two
filovirus
ebov
marburg
also
support
antivir
effect
favipiravir
compar
untreat
anim
reduc
level
viral
rna
extend
surviv
time
observ
ebovinfect
nonhuman
primat
wherea
marvinfect
nonhuman
primat
surviv
upon
treatment
favipiravir
proofofconcept
trial
favipiravir
patient
evd
guinea
initi
patient
receiv
favipiravir
along
standard
care
data
safeti
effect
favipiravir
reduc
mortal
viral
load
collect
studi
report
lower
fatal
rate
among
patient
low
moder
viral
load
compar
control
group
find
support
fpv
trial
sierra
leon
differ
part
guinea
studi
effect
favipiravir
favipiravir
approv
treatment
diseas
februari
china
pilot
studi
nonrandom
control
trial
third
peopl
hospit
shenzhen
report
significantli
better
treatment
effect
term
diseas
progress
viral
clearanc
compar
lopinavirritonavir
treatment
differ
random
clinic
trial
conduct
three
hospit
china
zhongnam
hospit
wuhan
univers
leishenshan
hospit
third
peopl
hospit
hubei
provinc
compar
efficaci
safeti
favipiravir
arbidol
treat
patient
trial
recruit
total
patient
follow
feb
mar
patient
experiment
group
receiv
variou
dose
mg
favipiravir
compar
patient
treat
multipl
antivir
drug
kaletra
oseltamivir
hydroxychloroquin
favipiravirtr
patient
found
higher
clinic
recoveri
rate
effect
reduc
incid
fever
cough
manifest
mild
moder
symptom
initi
stage
multipli
bind
angiotensinconvert
enzym
receptor
human
cell
clinic
trial
favipiravir
monotherapi
combin
drug
therapi
current
ongo
china
thailand
evalu
efficaci
safeti
favipiravir
treatment
diseas
still
insuffici
data
determin
mechan
action
favipiravir
treatment
patient
diagnos
contrast
remdesivir
favipiravir
chloroquin
cq
antimalari
drug
consid
one
drug
candid
exhibit
good
inhibitori
effect
cellular
level
chloroquin
synthes
effect
substitut
natur
quinin
use
malaria
figur
chloroquin
wide
use
treat
human
diseas
amoebiosi
autoimmun
diseas
wide
rang
bacteri
fungal
viral
infect
studi
also
report
versatil
antivir
activ
rna
virus
divers
rabi
viru
polioviru
hiv
hepat
virus
influenza
virus
ebola
viru
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
termin
nitrogen
spacer
blue
box
design
impart
parasit
resist
wherea
quinolon
nucleu
red
box
small
electron
withdraw
group
green
box
pivot
bind
hematin
halt
format
hemozoin
respect
chloroquin
administ
treat
malaria
chloroquin
weak
base
accumul
lowph
organel
endosom
golgi
vesicl
lysosom
interfer
acidif
hamper
lowphdepend
step
protein
degrad
viral
replic
includ
fusion
uncoat
addit
alter
glycosyl
cellular
receptor
virus
may
affect
viral
bind
potenti
activ
chloroquin
coronavirus
demonstr
differ
vitro
studi
chloroquin
success
inhibit
viral
replic
sarscov
merscov
ebov
variou
cell
line
anim
studi
hand
reveal
mix
result
treatment
chloroquin
show
signific
protect
sarscov
ebov
report
high
toxic
mous
hamster
model
howev
studi
report
posit
result
ebov
treat
chloroquin
contradict
result
anim
studi
could
owe
rang
dose
test
wherebi
higher
dose
could
necessari
produc
consist
posit
result
howev
may
lead
poor
outcom
owe
increas
drug
relat
toxic
furthermor
chloroquin
may
effect
prophylact
treatment
owe
activ
earli
stage
viral
cycl
establish
resid
host
replic
incub
period
patient
initi
stage
diseas
mild
condit
recent
wang
et
al
report
antivir
drug
remdesivir
chloroquin
effect
prevent
replic
clinic
isol
clinic
trial
patient
also
demonstr
chloroquin
phosphat
superior
control
treatment
inhibit
exacerb
pneumonia
improv
lung
imag
find
promot
viru
neg
convers
shorten
diseas
cours
symptom
sever
stage
ill
covid
howev
data
care
consid
draw
definit
conclus
result
publish
support
trial
number
clinic
trial
treatment
use
cq
regist
chines
clinic
trial
registri
chloroquin
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
request
conduct
clinic
trial
approv
find
chloroquin
might
explor
investig
mechan
action
chloroquin
inhibit
complementari
medicin
also
use
fight
pandem
diseas
altern
medic
one
complementari
altern
medicin
use
shuang
huang
lian
kou
fu
ye
offici
use
januari
beij
administr
tradit
chines
medicin
tradit
chines
medicin
tcm
compris
three
medicin
plant
lonicera
japonica
g
scutellaria
baicalensi
g
forsythia
suspens
accord
pharmacopoeia
peopl
republ
china
often
wide
prescrib
chines
practition
treatment
high
fever
coma
respiratori
diseas
accord
professor
zhao
zhi
li
shanghai
tradit
chines
medicin
univers
scutellaria
baicalensi
acknowledg
middl
class
medicin
forsythia
suspens
low
class
medicin
record
shennong
classic
materia
medica
han
dynasti
accord
rank
medicin
valu
high
class
level
valu
term
pharmacolog
wherea
lonicera
japonica
use
medicin
plant
treatment
diseas
sinc
southern
northern
dynasti
mingyi
bielu
total
compani
manufactur
antidot
one
manufactur
hayao
compani
shuang
huang
lian
kou
fu
ye
categor
level
list
drug
best
qualiti
drug
tcm
accord
categor
nation
health
insur
project
china
complementari
medicin
sold
announc
made
wuhan
institut
virolog
articl
shanghai
institut
biolog
scienc
ca
claim
medicin
suppress
cell
cultur
accord
studi
collabor
shanghai
institut
materia
medica
howev
tcm
includ
guidelin
launch
nation
health
commiss
peopl
republ
china
prevent
updat
version
known
guidelin
diagnosi
treatment
version
report
china
prevent
report
china
news
find
limit
initi
laboratori
phase
insuffici
data
avail
confirm
tcm
suppress
clinic
trial
still
essenti
verifi
efficaci
result
shanghai
public
health
clinic
center
wuhan
tongji
hospit
initi
clinic
trial
shuang
huang
lian
kou
fu
ye
although
still
insuffici
scientif
evid
tcm
use
control
still
wide
use
beij
administr
tradit
chines
medicin
claim
one
tcm
use
prevent
sarscov
coronavirus
famili
strategi
use
treatment
sar
could
relev
furthermor
medicin
plant
tcm
known
antivir
function
util
allevi
influenza
restrain
sar
coronaviru
medicin
plant
tcm
similar
common
characterist
includ
heatclear
dri
damp
detoxif
antivir
activ
influenza
sar
exampl
lonicera
japonica
wide
use
control
sar
coronaviru
accord
state
administr
tcm
china
lonicera
japonica
second
use
medicin
plant
treat
influenza
viru
subtyp
accord
statist
report
beij
youan
hospit
capit
medic
univers
antivir
activ
might
owe
presenc
uniqu
compound
chlorogen
acid
baicalin
forsythosid
lonicera
japonica
scutellaria
baicalensi
forsythia
suspens
respect
shown
figur
chlorogen
acid
abund
lonicera
japonica
report
attenu
death
rate
influenzavirusinfect
mice
late
stage
infecti
cycl
downregul
nucleoprotein
protein
express
furthermor
chlorogen
acid
play
role
neuraminidas
blocker
inhibit
releas
newli
form
viru
particl
infect
cell
baicalin
flavon
glycosid
found
scutellaria
baicalensi
also
act
neuraminidas
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
blocker
activ
signal
pathway
induc
product
human
cell
nk
cell
attenu
pivot
key
replic
target
tnfreceptorassoci
factor
furthermor
forsythia
suspens
also
display
antivir
activ
attribut
presenc
uniqu
compound
forsythosid
treatment
influenza
chemic
constitu
result
reduct
viral
titer
differ
influenza
viru
subtyp
cell
cultur
owe
decreas
matrix
protein
protein
influenza
block
bud
process
virion
format
limit
spread
viru
chemic
constitu
chlorogen
acid
baicalin
forsythiasid
share
common
characterist
antivir
influenza
howev
antivir
activ
coronavirus
requir
investig
clarif
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
use
depend
sever
condit
symptom
differenti
patient
show
mild
clinic
symptom
dri
cough
fatigu
chest
tight
nausea
mild
cold
fever
fever
tcm
consist
atractylod
lancea
pericarpium
citri
reticulata
magnolia
officinali
agastach
rugosa
amomum
tsaoko
crevost
et
lemari
chines
ephedra
notopterygium
incisum
zingib
officinal
areca
catechu
compli
decoct
combin
prescrib
tcm
bu
huan
jin
zheng
qi
san
da
yuan
yin
adapt
medic
encyclopedia
gu
jin
yi
tong
da
quan
chapter
wu
youk
book
titl
epidem
diseas
wen
yi
lun
respect
dynasti
ming
accord
shin
ingredi
categor
base
method
known
system
chief
deputi
assist
tcm
philosophi
theori
atractylod
lancea
chief
ingredi
wherea
agastach
rugosa
pericarpium
citri
reticulata
magnolia
officinali
act
deputi
ingredi
zingib
officinal
areca
catechu
respons
assist
ingredi
provid
better
synergist
effect
among
herb
treat
patient
best
method
atractylon
figur
chemic
compound
present
chief
ingredi
atractylod
lancea
attenu
influenza
viru
within
day
signal
pathway
upregul
tolllik
receptor
tumor
necrosi
factor
receptorassoci
factor
mrna
express
lung
tissu
mice
infect
influenza
viru
figur
one
main
compound
atractylon
found
tcm
decoct
use
treat
patient
mild
symptom
inhibit
coronavirus
synergist
effect
tcm
could
similar
action
inhibit
influenza
trigger
signal
pathway
howev
studi
need
prove
mechan
action
decoct
recent
qing
fei
pai
du
tang
appli
treatment
patient
clinic
symptom
rang
mild
sever
case
incub
period
viral
multipl
extrapulmonari
system
hyperinflamm
syndrom
even
use
prevent
medicin
diseas
confirm
case
chines
provinc
report
cure
discharg
treatment
tcm
similarli
chines
govern
report
patient
diagnos
mild
case
number
case
evolv
mild
sever
approxim
administ
western
medicin
alon
compar
approxim
integr
chines
western
medicin
treatment
use
qing
fei
pai
du
tang
compris
medicin
plant
chines
atractylon
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
xing
shi
gan
tang
mxsgt
known
antipyret
effect
commonli
use
treat
pneumonia
influenza
respiratori
diseas
systemat
review
found
combin
mxsgt
western
medicin
significantli
increas
effect
rate
treatment
treat
pneumonia
p
efficaci
tcm
show
signific
improv
p
day
consumpt
decoct
effect
safe
treatment
communityacquir
pneumonia
effect
might
mediat
pig
bronchial
smooth
muscl
inhibit
neutrophil
enter
respiratori
airway
block
acetylcholinerg
histaminerg
receptorinduc
bronchial
contract
rat
final
reduc
neutrophil
inflamm
furthermor
play
role
decreas
yet
increas
copd
rat
model
addit
effect
acut
airway
system
ailment
decoct
also
regul
pathogenesi
influenza
viru
infect
cell
attenu
autophagi
marker
protein
classic
decoct
use
china
japan
gan
huang
tang
sgmht
inhibit
mast
cell
releas
substanc
inflamm
regul
viscera
function
promot
apoptosi
eosinophil
report
mrna
express
level
cytokin
decreas
associ
cytokin
upregul
direct
attenu
pulmonari
edema
suppress
nfkb
pathway
two
herb
aster
tataricu
belamcanda
chinensi
modifi
version
sgmht
contrast
tcm
mention
two
tcm
formula
xiao
cai
hu
tang
wu
ling
san
function
differ
exhibit
function
acut
airway
obstruct
xiao
cai
hu
tang
xcht
known
tcm
liver
treatment
particularli
chronic
hepat
b
tcm
modul
express
indirectli
suppress
hepat
b
viru
accord
western
blot
analys
real
time
pcr
result
synergist
effect
tcm
treatment
pneumonia
unknown
requir
full
elucid
futur
wu
ling
san
wl
use
treatment
impair
regul
bodi
fluid
homeostasi
china
japan
korea
wl
might
affect
signal
transduct
pathway
nfkb
mapk
demonstr
antiinflammatori
effect
like
mxsgt
treat
pneumonia
respiratori
diseas
lipopolysaccharid
stimul
macrophag
deriv
formul
qing
fei
pai
du
tang
four
combin
classic
tcm
show
abil
reduc
symptom
patient
restor
normal
bodi
temperatur
patient
stop
cough
patient
result
tcm
list
one
treatment
option
nation
health
commiss
nhc
peopl
republ
china
guidelin
diagnosi
treatment
version
effect
qing
fei
pai
du
tang
reach
patient
cure
patient
district
china
march
none
case
becam
sever
mild
condit
consumpt
qing
fei
pai
du
tang
xue
bi
jing
inject
establish
tcm
china
recommend
sever
symptom
patient
unlik
drug
undergo
convent
clinic
trial
phase
proceed
bedsid
bench
final
back
bedsid
approv
obtain
china
food
drug
administr
chines
societi
critic
care
medicin
consequ
annual
consumpt
tcm
china
treatment
pneumonia
diseas
reach
xue
bi
jing
inject
consist
numer
compound
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
illustr
figur
extract
five
medicin
plant
radix
salvia
miltiorrhia
rhizoma
chuanxiong
flo
carthami
angelica
sinensi
radix
paeonia
rubra
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
chemic
constitu
xue
bi
jing
inject
senkyunolid
safflor
yellow
paeoniflorin
ferul
acid
galloylpaeoniflorin
anhydrosafflor
yellow
b
oxypaeoniflorin
caffeic
acid
albiflorin
uridin
gallic
acid
guanosin
danshensu
protocatechu
aldehyd
hydroxysafflor
yellow
initi
develop
activ
blood
circul
remov
blood
stasi
cool
blood
clear
toxic
heat
howev
tcm
use
fight
effect
treat
sever
pneumonia
sever
stage
covid
significantli
reduc
mortal
approxim
elev
improv
pneumonia
sever
index
approxim
xue
bi
jing
inject
reliev
reduc
sever
pneumonia
trigger
inflamm
pathway
downregul
day
treatment
although
significantli
influenc
releas
leptin
suggest
antiendotoxin
effect
deploy
halt
releas
endogen
inflammatori
mediat
result
block
develop
system
inflammatori
respons
syndrom
occur
disrupt
inflamm
viciou
cycl
mechan
action
xue
bi
jing
inject
reduc
sever
pneumonia
patient
lower
side
effect
organ
function
result
indic
tcm
use
complementari
medicin
treatment
patient
pandem
diseas
howev
mechan
action
tcm
still
requir
investig
systemat
review
conduct
januari
march
includ
paper
publish
publish
march
report
drug
repurpos
tradit
chines
medicin
tcm
treatment
option
use
patient
differ
countri
reduc
public
bia
increas
comprehens
timeli
review
foster
balanc
pictur
avail
evid
review
perform
accord
criteria
use
prefer
report
item
systemat
review
prisma
statement
treatment
repurpos
drug
depend
abil
drug
inhibit
prolifer
bind
enzym
activ
site
viral
chain
termin
trigger
molecular
pathway
instanc
ritonavir
lopinavir
believ
bind
enzym
activ
site
use
togeth
inhibit
replic
lopinavir
alon
suscept
oxid
metabol
cytochrom
enzym
wherea
addit
ritonavir
inhibit
enzym
activ
therefor
combin
ritonavir
lopinavir
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
essenti
maintain
drug
efficaci
treatment
howev
mechan
action
oseltamivir
combin
kaletra
remain
unclear
need
experiment
valid
therefor
combin
ritonavir
lopinavir
essenti
maintain
drug
efficaci
treatment
function
prevent
bind
sarscov
pro
enzym
site
respons
replic
glycoprotein
furthermor
remdesivir
favipiravir
attenu
replic
prematur
termin
rna
transcript
chloroquin
show
potenti
antivir
effect
vitro
howev
lack
vivo
data
support
therapeut
treatment
infect
contrast
drug
mention
tcm
discuss
review
initi
use
treat
influenza
sar
act
neuraminidas
blocker
trigger
inflamm
pathway
block
releas
endogen
inflammatori
mediat
halt
inflamm
mechan
action
instead
rna
chain
termin
new
drug
effect
treatment
still
develop
clinic
trial
review
provid
framework
better
understand
mechan
action
repurpos
drug
tcm
involv
molecular
pathway
inhibit
viral
replic
sar
mer
hope
provid
insight
molecular
pathway
lead
develop
effect
drug
treatment
futur
howev
experiment
valid
need
provid
concret
evid
fund
research
receiv
extern
fund
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
